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Abstract: We analyzed publications and articles in the PubMed database about the use of trimethoprim and sulfame-
thoxazole (TMP-SMX) in dermatology. Literature published in the English language, at least in the past two decades, 
was reviewed. Specific dermatologic indications for TMP-SMX are few but it is often used as the second- or third- line 
agent. TMP-SMX is used to treat cutaneous nocardiosis and Aeromonas infections. TMP-SMX is a treatment option for 
cat — scratch disease, granuloma inguinale, melioidosis and Mycobacterium marinum/fortuitum cutaneous infections. 
TMP-SMX is an alternate choice for treatment of pyodermas and lymphogranuloma venereum. TMP-SMX has been 
used to treat acne vulgaris in tetracycline and erythromycin — resistant patients. TMP-SMX is still the preferred empiric 
antibiotic for methicillin — resistant Staphylococcus aureus skin and soft tissue infection in HIV positive population. 
TMP-SMX is used in dermatology to treat various skin conditions and is one of the most commonly prescribed sulfon-
amide drugs. TMP-SMX as monotherapy is an effective treatment option in many diseases but due to drug resistance, 
a combination therapy-usually of two drugs-may be considered.
Key words: trimethoprim, sulfamethoxazole, co-trimoxazole, dermatological indications, cutaneous infections, combi-
nation therapy.
Introduction
Trimethoprim-sulfamethoxazole (TMP-SMX) or co-trimoxazole is a combined chemother-
apeutic used in treatment of various bacterial, fungal and protozoal infections. Its manifold 
properties can find an implementation in various fields of medicine but there are not many 
publications regarding its dermatological use. TMP-SMX consists of two active pharmaceu-
tical ingredients in a fixed dose ratio of one part trimethoprim to five parts sulfamethox-
azole. The synergy between trimethoprim and sulfamethoxazole is effective in inhibition of 
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enzymes involved in the bacterial synthesis of tetrahydrofolic acid, which is essential in the 
bacterial nucleic acids synthesis. Sulfamethoxazole inhibits conversion of p-aminobenzoic 
acid (PABA) into dihydrofolic acid and trimethoprim blocks conversion of dihydrofolic acid 
into tetrafolic acid. Bacterial nucleic acid synthesis is selectively disrupted because bacteria 
are unable to transport exogenous folate through their cell walls [1]. Apart from its anti-
microbial properties, there are some reports that TMP-SMX can present anti-inflammatory 
and immunomodulatory effects, enhancing the basic mechanism of action. Several studies 
show that co-trimoxazole can modulate both innate and adaptive immune cells facilitating 
antimicrobial pathways. Increased chemotaxis of neutrophils plays an important role in 
dermatological diseases mediated by neutrophils such as pyoderma gangrenosum. Increased 
productivity in phagocytosis and intracellular killing by macrophages improve bactericidal 
activity in infectious dermatoses, in which pathogens are not easily accessible for the im-
mune system (mycobacterioses). There are some reports suggesting that TMP-SMX may 
reduce proliferation of lymphocytes. It’s worth emphasizing that inhibition of lymphocytes 
T is crucial in preventing allograft rejection. However, there is some inconsistency between 
the authors of these studies therefore, further investigations should be provided [2].
Many aerobic bacteria are inhibited by TMP-SMX in vivo. Susceptible organisms comprise: 
Enterobacteriaceae, Vibrio cholerae, Staphylococcus spp. (including MRSA), Streptococcus 
spp. (excluding Streptococcus pneumonia), Haemophilus influenzae, Morganella morganii, 
Moraxella spp., Aeromonas hydrophila, Brucella spp., Burkholderia spp., Bordetella pertussis, 
Xanthomonas (Stenotrophomonas) maltophilia, Pseudomonas spp. (excluding Pseudomonas 
aeruginosa), Yersinia spp., P. jiroveci, Plasmodium spp., Nocardia spp., Listeria monocy-
togenes, Isospora belli, Cyclospora spp., Mycobacterium marinum and Mycobacterium 
fortuitum. Co-trimoxazole exhibits minor activity against S. Pneumoniae, N. meningitidis 
and Enterococcus spp. It is vital to emphasize that Mycoplasma spp., Rickettsia spp., Myco-
bacterium tuberculosis and Treponema pallidum are resistant to TMP-SMX and should not 
be considered in treatment of these infections. The drug has also poor anaerobic activity.
Both TMP and SMX are well absorbed from the gastrointestinal tract. The half-lives of TMP 
and SMX in patients with normal renal function amount approximately to 11 (t = 8.6–17 h) 
and 9 (t = 9–11 h) hours, respectively. But along with progressive decrease of glomerular 
filtration rate (GFR), the half-live of TMP lengthens. In case of renal dysfunction, the half 
life of the major metabolite of SMX lengthens if GFR is 25 ml/min/1.73 m² or below. In 
elderly patients the clearance of SMX decreases. Regarding this information, in case of 
GFR > 30 ml/min we can prescribe the standard dose, if GFR is 15–30 ml/min a half of the 
standard dose should be considered and if GFR is below 15 ml/min it is not recommended 
to administer this drug.
TMP-SMX is widely distributed in body fluids and tissues such as: amniotic fluid and 
tissues of fetus, aqueous humor, cerebrospinal fluid, bile, secretions of the middle ear, spu-
tum, synovial fluid, saliva, secretions of vagina, secretions of prostate and intracellular fluids.
The drug has the pregnancy category C and should not be administered in pregnant 
women unless the benefits of using this drug in mother are significantly higher than the risk 
of damage in fetus. Moreover, TMP-SMX is not recommended in breast feeding women, 
especially during the first 6 weeks of newborns’ life [3].
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TMP-SMX may prolong the prothrombin time of patients receiving concomitant war-
farin by inhibiting metabolic clearance of warfarin. TMP-SMX can interfere with folic acid 
availability and the dosage of folic acid supplementation in patients taking methotrexate 
should be adjusted [1].
Common adverse effects of TMP-SMX are gastrointestinal and hypersensitivity reactions. 
Maculopapular eruptions are particularly common in patients with AIDS. Pustular eruptions, 
phototoxic eruptions, Sweet’s syndrome, Stevens-Johnson syndrome and toxic epidermal 
necrolysis have been reported. Other adverse effects include aplastic anemia, neutropenia, 
agranulocytosis, thrombocytopenia, headache, fatigue, tremor, drug-induced fever, cholestat-
ic hepatitis, crystalluria, nephrolithiasis and interstitial nephritis [1]. We should emphasize 
that these serious side effects have been reported but in practice, the events such as Sweet’s 
syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis and blood dyscrasias are 
infrequent and TMP-SMX may be considered as a relatively safe chemotherapeutic [3].
Dermatologic indications for TMP-SMX
There are a few specific dermatologic indications for TMP-SMX but this chemotherapeutic is 
often used as the second — or third-line agent when conventional therapy is ineffective (Table 1).
Table 1
Disease Treatment option —TMP/SMX Reference number
Acne vulgaris 2,3-line drug, 80/400 mg q.d. 4
MRSA SSTIs 1-line drug, 160/800 mg b.i.d. 9
Nocardiosis 1-line drug 160/800 mg (+ DDS 100–200 mg) q.d. 11
Granuloma inguinale (donovanosis): 2-line drug, 160/800 mg b.i.d. 12
M. marinum infections 1,2-line drug (part of a multidrug therapy) 160/800 mg b.i.d. 13
M. fortuitum infections 2,3-line drug (part of a multidrug therapy) 160/800mg b.i.d. 14
Aeromonas infections 2-line drug 160/800 mg b.i.d. (+ ceftriaxon) 17
Melioidosis 1-line drug 320/1600 mg b.i.d. (eradication phase) 18, 19
Cat-scratch disease 6–8 mg/kg of TMP component (in complicated cases of CSD) 20, 21
Lymphogranuloma venereum 2-line drug 80/400 mg b.i.d. 22
Pyoderma gangrenosum 2-line drug 160/800 mg b.i.d. 23, 24
q.d. — quaque die
b.i.d. — bis in die
DDS — dapsone
TMP/SMX — trimethoprim/sulfamethoxazole 
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TMP-SMX can be used in treatment of acne vulgaris, perioral dermatitis and rosacea. In 
many instances, acne vulgaris treated with macrolide and tetracycline antibiotics has been 
shown to be ineffective. The reason for this treatment failure can be microbial resistance 
but some authorities postulate that the source of this inadequate response to conventional 
antibiotics may be related to seborrhea [4]. High sebum excretion rates can lead to reduced 
drug concentrations in pilosebaceous units preventing therapeutic action of antibiotics. 
A major analysis of 255 acne patients treated for 6 months with either oral erythromycin 
(1 g/day), minocycline (100 mg/day), oxytetracycline (1 g/day) or co-trimoxazole (400 mg/day) 
found out that a reduced clinical response in the presence of a high sebum excretion rate 
was associated with the usage of all these antibiotics; apart from trimethoprim. Therefore, 
trimethoprim can be useful in such instances [5]. It is also vital to emphasize that antibiotic 
resistance of Propionibacterium acnes, an important target in acne treatment, is increasing 
and cross-resistant patterns may occur e.g. erythromycin-resistant strains of P. acnes may 
have cross-resistance to trimethoprim-sulfamethoxazole [6].
TMP-SMX is an oral anti-staphylococcal agent that can be potent in treatment of skin and 
soft tissue infections (SSTIs) caused by methicillin-resistant Staphylococcus aureus (MRSA). 
In order to treat these infections, clinicians’ frequent choices are antimicrobial agents such 
as trimethoprim - sulfamethoxazole, clindamycin, linezolid, doxycycline, rifampin, moxi-
floxacin and minocycline [7] but oral treatment of MRSA SSTIs still remains challenging 
due to discordance between in vitro susceptibility MRSA tests and in vivo effectiveness [8]. 
Recent studies show that patients with MRSA SSTIs treated with the higher dose of TMP-
SMX (320/1.600 mg twice daily) for 7 to 15 days had a similar rate of clinical resolution as 
patients treated with the standard dose of TMP-SMX (160/800 mg twice daily) for 7 to 15 days. 
Therefore, the higher dose of TMP-SMX may not be necessary [9]. The lower dose of 
TMP-SMX may also improve the tolerance of this drug and minimize gastrointestinal 
side effects.
TMP-SMX is still a preferred empiric antibiotic for MRSA SSTIs in HIV positive pop-
ulation. Research has indentified low CD4 counts, intravenous drug use, male to male 
sexual contacts, syphilis, end-stage renal disease and recent beta-lactam antibiotic use as 
risk factors for MRSA SSTIs in this population. We should emphasize that resistance rates 
to TMP-SMX in HIV positive population have increased but they remain lower than other 
antimicrobial agents [10].
Nocardiosis is an infectious disease, caused by Gram-positive bacilli of the order Acti-
nomycetales, that presents as a primary cutaneous infection or as a disseminated disease. It 
mainly affects immunosuppressed individuals but can also affect immunocompetent patients.
Cutaneous nocardiosis is an infection, which responds well to treatment with TMP-SMX, 
especially in case of a limited disease of relatively short duration. In severe, disseminated 
cases imipenem in monotherapy or in combination with amikacin should be instituted [11].
TMP-SMX is considered as an alternative regimen in treatment of granuloma inguinale 
(donovanosis): one double-strength (160 mg/800 mg) tablet orally twice a day for at least 
3 weeks and until all the lesion have been completely healed. Granuloma inguinale is an 
endemic disease in some tropical areas such as India, Papua, New Guinea, the Caribbean, 
central Australia and southern Africa and recommended treatment is doxycycline 100 mg 
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orally twice a day for at least 3 weeks. In case of inadequate response to the treatment, the 
addition of aminoglycoside (e.g.: gentamicin 1 mg/kg IV every 8 hours) may be useful [12].
TMP-SMX can be used in treatment of infections caused by a non-tuberculous species 
of Mycobacterium. Mycobacterium marinum can be found in non-chlorinated water with 
worldwide prevalence. It is the most common atypical Mycobacterium that causes oppor-
tunistic infections in humans. Deep and superficial cutaneous infections may occur. In 
superficial cutaneous infections TMP-SMX is a treatment option as monotherapy. Others 
include: minocycline, clarithromycin and doxycycline but treatment often should be based 
on combination therapy due to multi-drug resistance of Mycobacterium marinum [13].
Mycobacterium fortuitum is a fast-growing species that can cause a skin infection after 
minor surgical procedures, when aseptic environment is not adequate. Rapid growing my-
cobacteria as a group are resistant to conventional antimycobacterial agents used to treat 
tuberculosis but are susceptible to several other antibiotics. Clarithromycin, ciprofloxacin, 
amikacin and cefoxitin are considered as first-line drugs. Alternative drugs include: dox-
ycycline, imipenem, etambutol, co-trimoxazole and amoxicillin–clavulanic acid. The best 
treatment option has not been determined but a combined therapeutic regimen is usually 
needed [14].
Aeromonas bacteria may cause skin and soft tissue infections manifesting themselves as 
cellulitis, pustules, and furuncles. TMP-SMX is active against most species [15–17].
Melioidosis is an infection caused by the gram-negative bacterium Burkholderia pseudo-
mallei. This disease is endemic in South-East Asia and North Australia with rare occurrence 
in temperate countries. Any organ, including the skin, can be involved in melioidosis and 
clinical presentation ranges from a localized infection to an acute inflammatory reaction, sepsis 
and death [18]. TMP-SMX is an effective regimen in the oral phase of melioidosis treatment. 
According to a recently published, double-blind, randomized controlled trial, TMP-SMX is 
as well effective as TMP-SMX plus doxycycline in the oral phase of melioidosis treatment. 
Therefore, this is a preferable option on the basis of patients’ safety and tolerance [19].
Cat-scratch disease is generally not serious. Medical treatment is not usually needed. In 
complicated cases, the treatment with antibiotics such as trimethoprim-sulfamethoxazole, 
ciprofloxacin or azithromycin can be helpful. In AIDS patients and other people who have 
the weakened immune system, cat-scratch disease is more serious and the treatment with 
antibiotics, including gentamicin, is recommended [20, 21].
Lymphogranuloma venereum (LVG) is a sexually transmitted disease (STD) caused by 
the invasive serovars L1, L2 or L3 of Chlamydia trachomatis. LVG primary presents as a 
self-limited genital ulcer or papule but it can develop to major lesions. In advanced stages, 
it can be manifested as lymphadenitis, lymphangitis with tender inguinal and/or femoral 
lymphadenopathy. Rectal exposure to this pathogen may result in proctocolitis, which left 
untreated can lead to chronic, colorectal fistulas and strictures [12]. TMP-SMX can be a 
treatment option for lymphogranuloma venereum [1, 22] but 100 mg of doxycycline orally 
twice a day for 21 days is recommended as the first choice treatment [12].
Pyoderma gangrenosum manifests as deep ulcers, which can develop into chronic necrotic 
lesions. This disease can constitute a manifestation of paraneoplastic syndrome. Systemic 
treatment with corticosteroids and cyclosporine is documented in literature for a disseminated, 
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as well as for localized, disease and should be considered as the first-line therapy [23]. 
However, corticosteroids have a lot of side effects e.g.: glucose intolerance and high arterial 
pressure. According to the case report about relapsing facial pyoderma gangrenosum (ma-
lignant pyoderma), sulfa drugs and minocycline may be considered as an alternative therapy 
in treatment of pyoderma malignum but further results should be provided [24].
TMP-SMX may be considered as an option for topical treatment of uncomplicated and 
superficial skin infections such as impetigo and other skin infections caused by S.aureus. 
One study exhibits that S. aureus isolates have low resistant rates to topical TMP-SMX but 
there are not many publications confirming the effectiveness of topical treatment and further 
investigation should be provided [25].
Conclusions
TMP-SMX is a potent antimicrobial agent that has several advantages. It may be administered 
in penicillin - allergic patients. The standard dose of TMP-SMX (160/800 mg twice daily) is 
still effective with minimal gastrointestinal side effects. TMP-SMX is currently a therapeutic 
option in treatment of MRSA SSTIs. This chemotherapeutic pharmacokinetically penetrates 
adequately into tissue compartments including abscesses. It can be taken orally and intra-
venous administration should be limited to situations in which immediate treatment must 
be provided or a patient is unable to take this drug orally. Trimethoprim-sulfametoxazole 
is used in dermatology to treat various skin conditions and is one of the most commonly 
prescribed sulfonamide drugs. Trimethoprim-sulfametoxazole as monotherapy is an effective 
treatment option in many diseases but due to drug resistance, a combination therapy — 
usually of two drugs — may be considered.
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